Aktuellt
SENASTE
After a period of steady increase in both European Idefirix sales and patient usage, Hansa records a softer Q4, with sales limited to SEK 25.6m. Hansa does not expect to record any material provisions related to retroactive discounts after 2024. Hansa enters 2025 with a more significant number of centres using Idefirix and improved support from European guidelines.
LÄS MER
